MedTrace Logo

A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration

NCT03249740 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2019-12-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.

Conditions

  • Neovascular Age-Related Macular Degeneration

Interventions

DRUG

GB-102

Intravitreal injection of GB-102

DRUG

Aflibercept

Intravitreal injection of Aflibercept.

Sponsors & Collaborators

  • Graybug Vision

    lead INDUSTRY

Principal Investigators

  • Charles P. Semba, MD · Graybug Vision, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-08-29
Primary Completion
2018-09-13
Completion
2019-01-16
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03249740 on ClinicalTrials.gov